Corebridge Financial’s Cullinan Oncology CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-25,603
Closed -$194K 531
2025
Q1
$194K Sell
25,603
-116
-0.5% -$1.11K ﹤0.01% 2101
2024
Q4
$313K Sell
25,719
-1,941
-7% -$27.9K ﹤0.01% 1919
2024
Q3
$463K Buy
27,660
+6,864
+33% +$122K ﹤0.01% 1771
2024
Q2
$363K Buy
+20,796
New +$443K ﹤0.01% 1867

Other funds holding CGEM

Corebridge Financial's CGEM Position: Q2 2025 in Review

Corebridge Financial sold out of Cullinan Oncology (CGEM) in Q2 2025, closing a stake of 25,603 shares — an estimated $194K sold.

Corebridge Financial first reported a position in CGEM in Q2 2024 and held it in 4 quarters. The position peaked at $463K in Q3 2024. 143 funds tracked by Wall St. Rank hold CGEM as of Q2 2025.

  • Corebridge Financial reported no remaining Cullinan Oncology position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 25,603 Cullinan Oncology shares in Q2 2025, an estimated $194K.
  • Corebridge Financial first reported a position in Cullinan Oncology in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Cullinan Oncology position peaked at $463K in Q3 2024.
  • 143 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.